Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0305119 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Lei Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Analgesics, Opioid, Immunotherapy, Inflammation, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study evaluated the effect of the systemic immune-inflammation index/albumin ratio (SII/ALB) on the prognosis of immunotherapy-treated patients receiving opioids.
Methods
A retrospective analysis was conducted of 185 immunotherapy-treated patients who received opioids at Xuzhou Central Hospital from 01/09/2021 to 01/09/2023. The results of related clinical data were collected during the week before the cancer patients received immunotherapy. The SII/ALB cut-off value was determined, and the relationship between the SII/ALB and clinical pathological parameters was analyzed using the chi-square test. The effect of the SII/ALB on progression-free survival (PFS) was examined using Kaplan-Meier curves and the Cox proportional hazard model.
Result
The SII/ALB cut-off value was 20.86, and patients were divided into low (SII/ALB ≤ 20.86) and high (SII/ALB > 20.86) SII/ALB groups. Adverse reactions (hazard ratio [HR] = 0.108; 95% confidence interval [CI]: 0.061–0.192, P < 0.001) and the SII/ALB (HR = 0.093; 95% CI: 0.057–0.151, P < 0.001) were independent prognostic factors for PFS. Compared with the high SII/ALB group, the low SII/ALB group had longer PFS after opioid treatment (12.2 vs. 5.2 months, P < 0.001).
Conclusion
The SII/ALB is a potentially important prognostic parameter in immunotherapy-treated patients receiving opioids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou Central Hospital Affiliated to Nanjing University of Chinese Medicine, The Xuzhou School of Clinical Medicine…
ORCID-Profile: Liu Yong
Zitieren
APA
Yan, L., Kang, P., Cao, C., Jinhui, B., & Yong, L. (2024). Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids. PLOS ONE. https://doi.org/10.1371/journal.pone.0305119
Vancouver
Yan L, Kang P, Cao C, Jinhui B, Yong L. Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids. PLOS ONE. 2024. doi:10.1371/journal.pone.0305119
BibTeX
@article{Yan2024,
author = {Yan, Lei and Kang, Pan and Cao, Chengsong and Jinhui, Bu and Yong, Liu},
title = {Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0305119}
}
EUVIMED